Compare AVXL & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVXL | GNE |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.9M | 382.1M |
| IPO Year | 2013 | 2011 |
| Metric | AVXL | GNE |
|---|---|---|
| Price | $3.24 | $13.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $22.00 | $16.00 |
| AVG Volume (30 Days) | ★ 2.0M | 46.1K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $425,202,000.00 |
| Revenue This Year | N/A | $17.49 |
| Revenue Next Year | N/A | $7.07 |
| P/E Ratio | ★ N/A | $18.22 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.61 | $13.27 |
| 52 Week High | $13.99 | $28.47 |
| Indicator | AVXL | GNE |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 45.19 |
| Support Level | $2.93 | $13.45 |
| Resistance Level | $4.88 | $14.85 |
| Average True Range (ATR) | 0.19 | 0.37 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 87.02 | 29.49 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.